360° Micropulse laser trabeculoplasty versus medical therapy in open-angle glaucoma: a randomized trial of efficacy, safety, and anterior segment morphological changes
Objective To evaluate the efficacy, safety, quality of life improvement, and morphological effects on the trabecular meshwork-Schlemm's canal outflow pathway of 360° MicroPulse Laser Trabeculoplasty (MLT) compared with guideline-escalated medical therapy in patients with open-angle glaucoma (OAG). Methods This prospective, randomized, parallel-group trial enrolled 90 patients with diverse OAG subtypes between February and April 2026. Participants were randomly assigned (1:1) to receive either 360° MLT (577 nm, 1000 mW, 15% duty cycle) or stepped medical therapy for 6 months. Primary outcomes included intraocular pressure (IOP) reduction, corneal endothelial cell density, and anterior segment optical coherence tomography (AS-OCT) quantification of Schlemm's canal diameter at baseline and month 3. Secondary outcomes comprised medication burden, Glaucoma Quality of Life-15 (GQL-15) scores, and adverse events. Results At 6 months, MLT achieved superior IOP reduction compared with medication (30.6% vs 21.8%; between-group difference 2.2 mmHg [95% CI: 1.1–3.3], P = 0.003). At month 3, AS-OCT demonstrated significant Schlemm's canal dilation with MLT (+37.2 μm, P < 0.001) but not medication. Corneal endothelium remained stable in both groups. MLT reduced medication burden by 61.1% (37.8% medication-free) versus no change with medication. GQL-15 scores improved more with MLT (5.8 vs. 1.1 points, P < 0.001). MLT had no serious adverse events; medication-related adverse events requiring intervention occurred only in the medication group (26.7% vs. 0%). Conclusions 360° MLT provides superior IOP control, reduced medication burden, and improved quality of life compared with medical therapy, and was associated with dilation of Schlemm's canal—a morphological change consistent with enhanced conventional aqueous outflow. These findings support MLT as an effective, medication-sparing early intervention for open-angle glaucoma. Clinical Trial Registration https://www.chictr.org.cn/showproj.html?proj=293191 , Number: ChiCTR2600117484; Registration Date: 20260126
Authors
- Na He (ORCID: https://orcid.org/0000-0003-1066-0478)
- Jing Bao (ORCID: https://orcid.org/0000-0002-8046-2525)
- Jialing He (ORCID: https://orcid.org/0009-0000-4118-3649)
- Peiling Xie
- Xiaochun Li
Institutions
- Jinhua Central Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fmed.2026.1985905
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00